Immunocore Holdings plc Total Long-Term Debt
Immunocore Holdings plc (IMCR) had Total Long-Term Debt of $438.69 million as of 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LongTermDebt · last filed 2024-11-06
- 2024-09-30: Long-term Debt $438.69M.
- 2024-06-30: Long-term Debt $452.50M.
- 2024-03-31: Long-term Debt $452.50M.
- 2024-02-02: Long-term Debt $402.50M.
| Period end | Long-term Debt |
|---|---|
| 2024-09-30 | $438.69M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $452.50M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $452.50M 10-Q · filed 2024-05-08 |
| 2024-02-02 | $402.50M 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |